Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
11 hedge funds and large institutions have $689K invested in Rosetta Genomics Ltd. in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.
38% more funds holding
Funds holding: 8 → 11 (+3)
12% less capital invested
Capital invested by funds: $780K → $689K (-$91K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$377K |
| 2 |
Morgan Stanley
New York
|
+$74.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$27.1K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$25K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
+$2.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$52.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$4.67K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$1.76K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $248K | +$377K | +49,278 | New |
|
|
2
Morgan Stanley
New York
| $190K | +$74.2K | +9,700 | +34% |
|
|
HCM
3
Highlander Capital Management
Short Hills,
New Jersey
| $170K | -$52.7K | -6,888 | -17% |
|
|
VKH
4
Virtu KCG Holdings
New York
| $27K | +$25K | +3,272 | +162% |
|
5
California Public Employees Retirement System
Sacramento,
California
| $21K | – | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| $18K | +$27.1K | +3,545 | New |
|
|
TSS
7
Two Sigma Securities
New York
| $9K | -$1.76K | -230 | -12% |
|
|
8
UBS Group
Zurich,
Switzerland
| $4K | -$4.67K | -610 | -46% |
|
9
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
10
SEI Investments
Oaks,
Pennsylvania
| $1K | +$2.07K | +271 | New |
|
ROSG Hedge Fund Activity: Q4 2016 in Review
11 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q4 2016, worth a combined $689K — down 12% from $780K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ROSG positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $377K. The largest seller was Highlander Capital Management, cutting an estimated $52.7K.
- 11 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q4 2016, up from 8 in Q3 2016.
- Funds reported $689K of Rosetta Genomics Ltd. stock for Q4 2016, down 12% quarter-over-quarter.
- 3 funds opened new Rosetta Genomics Ltd. positions in Q4 2016 and 0 closed out, a net change of +3 holders.
- The largest Rosetta Genomics Ltd. buyer in Q4 2016 was Sabby Management, an estimated $377K added.
- The largest Rosetta Genomics Ltd. seller in Q4 2016 was Highlander Capital Management, an estimated $52.7K sold.
Based on aggregated 13F filings for Q4 2016.